Auour Investments’s Atea Pharmaceuticals AVIR Stock Holding History

Auour Investments’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$952K	Hold	177,000	–	–	0.3%	45
2025 Q4	$632K	Hold	177,000	–	–	0.2%	52
2025 Q3	$513K	Hold	177,000	–	–	0.17%	52
2025 Q2	$637K	Hold	177,000	–	–	0.22%	47
2025 Q1	$522K	Hold	177,000	–	–	0.19%	49
2024 Q4	$542K	Hold	177,000	–	–	0.19%	50
2024 Q3	$600K	Hold	177,000	–	–	0.21%	49
2024 Q2	$586K	Hold	177,000	–	–	0.22%	48
2024 Q1	$715K	Hold	177,000	–	–	0.26%	48
2023 Q4	$671K	Hold	177,000	–	–	0.26%	46
2023 Q3	$535K	Hold	177,000	–	–	0.23%	46
2023 Q2	$662K	Buy	+177,000	New	+$663K	0.28%	45

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Auour Investments's AVIR Position: Q1 2026 in Review

Auour Investments held its Atea Pharmaceuticals (AVIR) position steady in Q1 2026 at 177,000 shares worth $952K. The position accounts for 0.3% of the portfolio, ranked #45.

Auour Investments first reported a position in AVIR in Q2 2023 and has held it in 12 quarters since. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

Auour Investments held 177,000 shares of Atea Pharmaceuticals worth $952K as of Q1 2026.
Auour Investments left its Atea Pharmaceuticals share count unchanged in Q1 2026.
Atea Pharmaceuticals made up 0.3% of Auour Investments's portfolio in Q1 2026, its #45 holding.
Auour Investments first reported a position in Atea Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Auour Investments's 13F filing for Q1 2026, filed 20 Apr 2026.